Decoy Therapeutics Inc. (DCOY) is a Healthcare stock trading at $3.20 (as of 2026-08-21), with a market capitalization of $2.10M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company focused on using machine learning and other AI tools together with rapid synthesis methods to design, engineer, and manufacture peptide-conjugate drug candidates. The company is headquartered in Cambridge, Massachusetts.
Decoy Therapeutics uses machine learning, AI tools, and high-speed synthesis to design, engineer, and manufacture peptide conjugate drug candidates for serious unmet medical needs; as a preclinical-stage company, it is not yet generating reported product revenue.
Its profit model is currently an investment in drug discovery, with no reported revenue and operating losses while candidates remain preclinical.
Business quality (Unprofitable): Unprofitable, with operating margin -1156%.
| Price | $3.20 |
| Market Cap | $2.10M |
| Price / Book | 0.49 |
| Revenue (TTM) | $0.00 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | Warberg Asset Management LLC ($18178.00) |
| Institutional Holders Tracked | 8 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Frederick E. Pierce |
| Employees | 2 |
| Country | US |
| IPO Date | 2015-01-29 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.